| 标题 |
379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) |
| 网址 | |
| DOI | |
| 其它 |
期刊:European Journal of Cancer Supplements 作者:R. Kurzrock; S. Sherman; D. Hong; C. Ng; J. Frye; et al 出版日期:2008 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)